LEDERLE LEUCOVORIN-PWS IM IV 350MG/VIAL 350 MG — DIN 02170507
LEUCOVORIN (LEUCOVORIN CALCIUM) : 350 MG · WYETH-AYERST CANADA INC. · POWDER FOR SOLUTION · wholesale supply in Canada
Health Canada status: CANCELLED POST MARKET
What is LEDERLE LEUCOVORIN-PWS IM IV 350MG/VIAL?
LEDERLE LEUCOVORIN-PWS IM IV 350MG/VIAL 350 MG contains LEUCOVORIN (LEUCOVORIN CALCIUM) : 350 MG. It is listed in the Health Canada Drug Product Database under DIN 02170507, held by WYETH-AYERST CANADA INC., supplied as POWDER FOR SOLUTION for INTRAVENOUS ; INTRAMUSCULAR administration. Health Canada currently lists it as cancelled post market, status dated 17-May-2002. This Drug Identification Number is no longer authorized for sale in Canada, so Nexara does not supply it. The record is kept here because buyers still meet the number on old formularies, purchase orders and tender documents; Nexara can help identify an authorized alternative.
Is there a generic Calcium Folinate in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
10 holders have a Canadian DIN containing Calcium Folinate, across 21 DINs, of which 9 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| PFIZER CANADA ULC | 3 | 3 | LEDERLE LEUCOVORIN, LEUCOVORIN CALCIUM INJECTION USP | Sourceable in Canada |
| GENERIC MEDICAL PARTNERS INC | 3 | 2 | LEUCOVORIN CALCIUM INJECTION | Sourceable in Canada |
| JAMP PHARMA CORPORATION | 2 | 1 | JAMP LEUCOVORIN, LEUCOVORIN CALCIUM INJECTION USP | Sourceable in Canada |
| LABORATOIRE RIVA INC. | 1 | 1 | RIVA LEUCOVORIN | Sourceable in Canada |
| MINT PHARMACEUTICALS INC | 1 | 1 | MINT-LEUCOVORIN | Sourceable in Canada |
| TEVA CANADA LIMITED | 1 | 1 | LEUCOVORIN CALCIUM INJECTION | Sourceable in Canada |
| LEDERLE CYANAMID CANADA INC. | 4 | 0 | LEDERLE LEUCOVORIN 350MG/VIAL, LEDERLE LEUCOVORIN 50MG/VIAL, LEDERLE LEUCOVORIN LIQ 10MG/ML, LEUCOVORIN CALCIUM TAB 5MG | No marketed DIN |
| WYETH-AYERST CANADA INC. | 3 | 0 | LEDERLE LEUCOVORIN - LIQ IM IV 10MG/ML, LEDERLE LEUCOVORIN-PWS IM IV 350MG/VIAL, LEDERLE LEUCOVORIN-PWS IM IV 50MG/VIAL | No marketed DIN |
| DAVID BULL LABORATORIES (PTY) LTD. | 2 | 0 | LEUCOVORIN CA INJ (PHARM. BULK VIAL) 10MG/ML, LEUCOVORIN CALCIUM INJ 10MG/ML | No marketed DIN |
| SANDOZ CANADA INCORPORATED | 1 | 0 | LEUCOVORIN CALCIUM INJECTION | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 350 MG |
|---|---|
| Dosage form | POWDER FOR SOLUTION |
| Route | INTRAVENOUS ; INTRAMUSCULAR |
Pack detail is kept as a regulatory record. This DIN is no longer authorized for sale in Canada, so Nexara does not quote this pack.
Substance and classification
| Active substance | Calcium Folinate |
|---|---|
| ATC code | V03AF03 |
| AHFS class | 91:04.12 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02170507 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2170507 |
| Brand name | LEDERLE LEUCOVORIN-PWS IM IV 350MG/VIAL |
| Generic / active ingredient | LEUCOVORIN (LEUCOVORIN CALCIUM) : 350 MG |
| Market authorization holder | WYETH-AYERST CANADA INC. |
| Health Canada schedule | Prescription |
| ATC code | V03AF03 |
| ATC anatomical main group | V — Various |
| ATC therapeutic subgroup | V03AF |
| Current status | CANCELLED POST MARKET |
| Status date | 17-May-2002 |
| Original market date | 1997-02-04 00:00:00 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Calcium Folinate in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Anticipated — reported by PFIZER CANADA ULC, last seen 09 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
Check availability for LEDERLE LEUCOVORIN-PWS IM IV 350MG/VIAL
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
9 of 21 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| JAMP LEUCOVORIN | 5 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | 02548208 |
| LEDERLE LEUCOVORIN | 5 MG | TABLET | PFIZER CANADA ULC | MARKETED | 02170493 |
| LEUCOVORIN CALCIUM INJECTION | 1000 MG / 100 ML | SOLUTION | GENERIC MEDICAL PARTNERS INC | MARKETED | 02496925 |
| LEUCOVORIN CALCIUM INJECTION | 10 MG | SOLUTION | TEVA CANADA LIMITED | MARKETED | 02087316 |
| LEUCOVORIN CALCIUM INJECTION | 10 MG | SOLUTION | GENERIC MEDICAL PARTNERS INC | MARKETED | 02480042 |
| LEUCOVORIN CALCIUM INJECTION USP | 10 MG | Solution | PFIZER CANADA ULC | MARKETED | 02183005 |
| LEUCOVORIN CALCIUM INJECTION USP | 10 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | 02182998 |
| MINT-LEUCOVORIN | 5 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | 02496828 |
| RIVA LEUCOVORIN | 5 MG | TABLET | LABORATOIRE RIVA INC. | MARKETED | 02493357 |
| LEDERLE LEUCOVORIN - LIQ IM IV 10MG/ML | 10 MG | LIQUID | WYETH-AYERST CANADA INC. | CANCELLED POST MARKET | 02170485 |
2 · Same class — other molecules in ATC V03AF
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Calcium Folinate | JAMP LEUCOVORIN · LEDERLE LEUCOVORIN · LEDERLE LEUCOVORIN - LIQ IM IV 10MG/ML · LEDERLE LEUCOVORIN 350MG/VIAL · +11 more | 21 | 9 | Yes |
| Dexrazoxane | DEXRAZOXANE FOR INJECTION · ZINECARD | 5 | 3 | Yes |
| Mesna | MESNA FOR INJECTION · UROMITEXAN · UROMITEXAN INJ 100MG/ML | 4 | 3 | Yes |
| Rasburicase | FASTURTEC | 2 | 1 | Yes |
| Amifostine | ETHYOL - PWS IV 500MG/VIAL | 1 | 0 | Not in Canada |
| Palifermin | KEPIVANCE | 1 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC V03A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| V03AC | Deferasirox · Deferiprone · Deferoxamine | 57 | 44 |
| V03AN | Carbon Dioxide · Combination · Helium · Medical Air · Medical Gases · +2 more | 112 | 43 |
| V03AB | Amyl Nitrite · Andexanet Alfa · Antidotes · Digitalis Antitoxin · Dimercaprol · +16 more | 87 | 31 |
| V03AE | Calcium Acetate · Drugs For Treatment Of Hyperkalemia And Hyperphosphatemia · Lanthanum Carbonate · Patiromer Calcium · Polystyrene Sulphonate · +3 more | 40 | 19 |
| V03AH | Diazoxide | 2 | 1 |
| V03AX | Cobicistat · Difelikefalin · Other Therapeutic Products | 8 | 1 |
| V03AZ | Ethanol | 1 | 0 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.